Evaluation of Initial and Steady-State Gatifloxacin Pharmacokinetics and Dose in Pulmonary Tuberculosis Patients by Using Monte Carlo Simulations

Wynand Smythe, Corinne S. Merle, Roxana Rustomjee, Martin Gninafon, Mame Bocar Lo, Oumou Bah-Sow, Piero L. Olliaro, Christian Lienhardt, John Horton, Peter Smith, Helen McIlleron and Ulrika S. H. Simonsson

Published Ahead of Print 17 June 2013.
Evaluation of Initial and Steady-State Gatifloxacin Pharmacokinetics and Dose in Pulmonary Tuberculosis Patients by Using Monte Carlo Simulations

Wynand Smythe, Corinne S. Merle, Roxana Rustomjee, Martin Gninafon, Mame Bocar Lo, Oumou Bah-Sow, Piero L. Olliaro, Christian Lienhardt, John Horton, Peter Smith, Helen Mcilleron, Ulrika S. H. Simonsson

Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa; Faculty of Epidemiology & Population Health, Tropical Epidemiological Group, London School of Hygiene & Tropical Medicine, London, United Kingdom; Unit for Clinical & Biomedical TB Research, Medical Research Council (MRC), Durban, South Africa; Programme National de Lutte contre la Tuberculose, Cotonou, Benin; Programme National de Lutte contre la Tuberculose, Dakar-Fann, Senegal; Service Pneumo-phtisiologie, CHU Ignace Deen, Conakry, Guinea; UNICEF/UNDP/World Bank/WHO Special Programme on Research & Training in Tropical Diseases (TDR), World Health Organization, Switzerland; Institut de recherche pour le Développement (IRD), Paris, France; Tropical Projects, Hitchin, United Kingdom; Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa; Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden

A 4-month regimen of gatifloxacin with rifampin, isoniazid, and pyrazinamide is being evaluated for the treatment of tuberculosis in a phase 3 randomized controlled trial (OFLOTUB). A prior single-dose study found that gatifloxacin exposure increased by 14% in the combination regimen. The aims of the study are to evaluate the initial and steady-state pharmacokinetics of gatifloxacin when daily doses are given to patients with newly diagnosed drug-sensitive pulmonary tuberculosis as part of a combination regimen and to evaluate the gatifloxacin dose with the probability of attaining a pharmacokinetic/pharmacodynamic target. We describe the population pharmacokinetics of gatifloxacin from the first dose to a median of 28 days in 169 adults enrolled in the OFLOTUB trial in Benin, Guinea, Senegal, and South Africa. The probability of achieving a ratio of ≥125 for the area under the concentration time curve to infinity (AUC0–∞)/MIC was investigated using Monte Carlo simulations. The median AUC0–∞ of 41.2 µg · h/ml decreased on average by 14.3% (90% confidence interval [CI], −90.5% to +61.5%) following multiple 400-mg daily doses. At steady state, 90% of patients achieved an AUC/MIC of ≥125 only when the MIC was <0.125 µg/ml. We conclude that systemic exposure to gatifloxacin declines with repeated daily 400-mg doses when used together with rifampin, isoniazid, and pyrazinamide, thus compensating for any initial increase in gatifloxacin levels due to a drug interaction. (The OFLOTUB study has been registered at ClinicalTrials.gov under registration no. NCT00216385.)

Fluoroquinolones represent a promising class of drug for the treatment of tuberculosis. Gatifloxacin distributes widely throughout the body (1), achieving MICs for Mycobacterium tuberculosis observed in vitro of 0.031 to 0.5 µg/ml (2, 3, 4), and demonstrates strong bactericidal activity in the mouse model (2, 5). Furthermore, gatifloxacin displays excellent early bactericidal activity (EBA), only slightly lower than that of isoniazid (6); replacing ethambutol with gatifloxacin in the standard first-line regimen resulted in accelerated killing of M. tuberculosis in the sputum of patients with pulmonary tuberculosis (7). A single-dose crossover study in healthy volunteers showed a reduction in the elimination rate of gatifloxacin resulting in a 14% increase in the area under the concentration time curve to infinity (AUC0–∞) when it was given together with rifampin, isoniazid, and pyrazinamide (8). Reports of dysglycemia related to the use of gatifloxacin in elderly patients with renal insufficiency (9, 10, 11, 12) have raised concerns that pharmacokinetic interactions may lead to an increased risk of toxicity related to higher gatifloxacin exposure. On the other hand, in vitro and in vivo studies suggest a target ratio of ≥125 for the free drug area under the concentration versus time curve to MIC (FAUC/MIC) for maximal bactericidal effect and prevention of resistance to fluoroquinolones (13, 14).

We aimed to evaluate the population pharmacokinetics of gatifloxacin after an initial dose and at steady state (28 days) when given in combination with rifampin, isoniazid, and pyrazinamide in African adult patients with newly diagnosed pulmonary tuberculosis. In addition, the probability of target (FAUC/MIC ≥125) attainment (PTA) and the cumulative fraction of response (CFR) across the MIC distribution of M. tuberculosis for 400, 600, and 800 mg once daily of gatifloxacin at steady state in combination with rifampin, isoniazid, and pyrazinamide were investigated with Monte Carlo simulations using the final model.

MATERIALS AND METHODS

Patients. Newly diagnosed pulmonary tuberculosis patients participating in the multicenter phase 3 randomized controlled trial (OFLOTUB trial [ClinicalTrials.gov registration no. NCT00216385]) at clinics in South Africa, Senegal, Guinea, and Benin were enrolled in the pharmacokinetic study, and those randomized to the 4-month regimen of gatifloxacin, rifampin, isoniazid, and pyrazinamide (n = 169) were included in this analysis. Written informed consent was obtained prior to enrollment. Adult males (n = 116) and nonpregnant females (n = 53), aged 18 to 58 years and weighing 35 to 80 kg were included in this analysis. HIV-infected patients (n = 54) were antiretroviral naive. During the first 2

Received 14 March 2013 Returned for modification 4 May 2013 Accepted 10 June 2013 Published ahead of print 17 June 2013

Address correspondence to Helen Mcilleron, helen.mcilleron@uct.ac.za.
Copyright © 2013, American Society for Microbiology. All Rights Reserved.

4164 aac.asm.org Antimicrobial Agents and Chemotherapy p. 4164–4171 September 2013 Volume 57 Number 9
months of treatment, all patients received 400 mg gatifloxacin (Lupin Pharmaceuticals Pvt Ltd., Mumbai, India) daily irrespective of weight together with a fixed combination of rifampin, isoniazid, and pyrazinamide (Lupin Pharmaceuticals Pvt Ltd., Mumbai, India) as follows: rifampin, 150 mg; isoniazid, 75 mg; and pyrazinamide, 400 mg; patients weighing <50 kg received 3 tablets, and patients weighing ≥50 kg received 4 tablets. All doses were given orally for 6 days of the week, and dose taking was supervised using directly observed therapy (DOT) performed either by health center staff or designated representatives for the duration of the study.

Blood sampling. Three venous blood samples per patient were taken after the first dose (initial dose) and repeated after approximately 28 days (steady state) for the determination of gatifloxacin pharmacokinetics. Samples were drawn 1 to 2 and 2.5 to 3.5 h postdose from each patient on both occasions. Patients were block randomized to a time for the third sample. After the first dose, the third sample was taken 4 to 6 h postdose from one half of the patients, and the remaining patients had a sample taken 8 to 10 h postdose. At steady state, the third sample was taken either predose, 4 to 6 h postdose, or 8 to 10 h postdose.

Drug quantification. Each 4-ml blood sample, collected in a heparinized vacuum plastic tube, was centrifuged at 750 × g for 10 min to separate the plasma using a benchtop centrifuge. Samples were kept on crushed ice during preparation, and the plasma aliquots were stored at −80°C until drug quantification within 30 min of sampling. Concentrations of gatifloxacin in plasma were quantified using high-performance liquid chromatography (HPLC) coupled to tandem mass spectrometry (MS). Inter- and intraday coefficients of variation were below 10%. The lower limit of quantification was set at 0.2 µg/ml for pyrazinamide and 0.1 µg/ml for rifampin, gatifloxacin, and isoniazid (8).

Population pharmacokinetic analysis. Data analysis was performed with a nonlinear mixed-effects approach, as implemented in NONMEM software, version 7.1.2 (Icon Development Solutions) (17), using Advan13 and the first-order conditional estimation method with interaction (FOCE Int). R (version 2.12.1) was used for graphical analysis and data management (18). Xpose (version 4.0) was used for data exploration and visualization as well as model diagnostics and model comparison (19). PsN, version 3.3.2 (20, 21), was used for stepwise covariate model building (SCM) (22), visual predictive checks (VPCs) (23, 24), and prediction-corrected VPCs (pVPCs) (25) of the models. Model selection was performed using the objective function value (OFV) (which is minus twice the log likelihood of the data), standard error of parameter estimates, scientific plausibility, and goodness-of-fit plots together with VPC and, when indicated, pVPC.

A total of 954 gatifloxacin concentration observations from 169 patients were included in the analysis. Twelve observations, from 12 individuals, falling below the lower limit of quantification (LLOQ = 0.1 µg/ml) were replaced with LLOQ/2. There was not more than one LQO observation in each individual absorption or elimination phase. One- and two-compartment distribution models with first-order elimination were fitted to the data. Potential differences in gatifloxacin pharmacokinetic parameters were evaluated after initial and multiple doses. A transit absorption compartment model described by Savic et al. (26) and applied by Wilkins et al. (27) for multiple dosing was used to capture the delay in the absorption characteristics. The absorption model used hypothetical transit compartments to mimic a delay in the onset of absorption, producing a gradual increase in absorption rate in a physiologically plausible manner. Drug transfer between transit compartments occurred via the rate constant $k_n$ (equation 1):

$$k_n = \frac{N + 1}{MTT} \quad (1)$$

where $MTT$ is the mean transit time and $N$ is the number of transit compartments. Drug transfer from the final transit compartment to the central compartment occurred via the first-order rate constant $k_s$.

Creatinine clearance ($CL_{CRE}$) was estimated from serum creatinine using the Cockcroft-Gault formula (28) (equation 2):

$$CL_{CRE} = \frac{(140 - \text{age}) \cdot \text{MASS} \cdot K}{\text{serum creatinine}} \quad (2)$$

where $CL_{CRE}$ is in ml/min, serum creatinine is in mmol/ml, age is recorded in years, $K$ represents a constant of 1.23 for men and 1.04 for women, and MASS is the total body weight recorded in kilograms.

As gatifloxacin is excreted primarily via the kidneys (1), typical oral clearance, $TV(CL/F_{GFR})$, was parameterized as the sum of $TV(CL/F_{GFR})$ (where $GFR$ stands for glomerular filtration rate), accounting for drug being passively filtered through the kidneys, and $TV(CL/F_{other})$, accounting for the remaining drug clearance (equation 3):

$$TV CL F_{GFR} = TV CL F_{GFR} + TV CL F_{other} \quad (3)$$

The relationship between $TV(CL/F_{GFR})$ and $CL_{CRE}$ was parameterized using equation 4.

$$TV CL F_{GFR} = \frac{(CL F_{other} \cdot (\frac{CL_{CRE median}}{CL_{CRE median}}))}{(CL F_{other} \cdot (\frac{CL F_{other} median}{CL F_{other} median}))} \quad (4)$$

where $CL_{CRE median}$ is the oral clearance in a typical patient with a median $CL_{CRE}$ of 94 ml/min and $CL_{CRE median}$ is the individual $CL_{CRE}$. $TV(CL/F_{other})$ was scaled to a body size descriptor (MASS) and reported for a typical 70-kg patient ($[CL F_{other} median] = 1.23$) (equation 5):

$$TV CL F_{other} = \frac{(CL F_{other} \cdot (\frac{MASS}{70}))}{(CL F_{other} \cdot (\frac{MASS}{70}))} \quad (5)$$

Allometric scaling, using various size descriptors (MASS), namely, total body weight (WT) (29, 30, 31, 32), fat-free mass (FFM) (32, 33), and normal fat mass (NFM) (33), was evaluated for both $TV(CL/F_{other})$ (equation 5) and the typical apparent volume of distribution, $TV(V/F)$ (equation 6):

$$TV V F_{STD} = \frac{(V F) \cdot (\frac{MASS}{70})}{(V F) \cdot (\frac{MASS}{70})} \quad (6)$$

where $(V/F)_{STD}$ is the typical apparent volume of distribution. NFM was expressed for $TV(CL/F_{other})$ (equation 7) and $TV(V/F)$ (equation 8) as described by Anderson and Holford (33).

$$NFM = FFM + (F_{fat} \cdot CL_{F_{fat}} \cdot (WT - FFM)) \quad (7)$$

$$NFM = FFM + (F_{fat} \cdot \frac{1}{2} \cdot (WT - FFM)) \quad (8)$$

where $(F_{fat})_{CL/F_{other}}$ and $(F_{fat})_{V/F}$ denote the estimated unique contribution of fat mass (i.e., body weight minus FFM) to $CL_{F_{other}}$ and $V/F$, respectively.

Individual FFM values ($FFM_i$) were calculated as

$$FFM_i = \frac{(WHS_{MAX} - HT^2 \cdot WT)}{WHS_{MAX} - HT^2 + WT} \quad (9)$$

where $WHS_{MAX}$ is 42.92 kg/m² and $WHS_{MIN}$ is 30.93 kg/m² in men, $WHS_{MAX}$ is 37.99 kg/m² and $WHS_{MIN}$ is 35.98 kg/m² in women, HT is height in meters, and WT is total body weight in kg.

Interindividual variability (IVV) was modeled exponentially for all parameters. Furthermore, interoccasion variability (IOV) in the pharmacokinetic parameters was explored for all parameters (34). Covariance between parameters was also tested. Different residual error models were investigated, including proportional and slope-intercept models. Shrinkage was calculated for fixed and random effects as 1 − SD (η)/ω, where η is the between-individual and -occasion variation term and ω is the population model estimate of the standard deviation in η.

Once the basic model was developed, a covariate analysis was performed using stepwise covariate model building (SCM) (22) as implemented in PsN version 3.3.2 (20, 21). Sex, age, HIV status, and study site (South Africa versus West Africa) were investigated as covariate effects on $CL/CL/F_{GFR}$, $CL/F_{other}$, $V/F$, $k_s$, $MTT$, and bioavailability (F). In the SCM, each parameter-covariate relationship was tested.
in a univariate fashion within NONMEM. The covariate model that resulted in the best fit was carried forward to a multivariate search in which the remaining parameter-covariate relations were included based on a 5% significance level, and it was referred to as the "full forward model." After identification of the full forward model, a backward deletion was performed to determine the final model. In the backward-deletion step, each parameter covariate relationship was left out one at a time and tested using a statistical significance criterion of 0.01%. This step was repeated until no further covariate could be excluded, and the resulting model was referred to as the "final model." Continuous covariates were first introduced in a linear fashion (fractional change) and centered on the median covariate value. If a continuous covariate was included in a linear fashion, inclusion according to a nonlinear fashion (i.e., piece-wise linear, exponential, and power equation) was also tested. For categorical covariates, models were expressed as fractional change from the typical value.

Based on the final model, the AUC from zero hour to infinity (AUC$_{0-\infty}$) was derived to describe exposure after the first dose and at steady state (day 28), respectively. Total oral clearance was simulated for 10,000 virtual patients and AUC$_{0-\infty}$ derived through the following equation:

$$\text{AUC}_{0-\infty} = \frac{F \cdot \text{dose}}{CL}$$

(10)

The individual percentage change in AUC$_{0-\infty}$ between first dose and steady state was calculated and reported as median (5th and 95th percentiles). The 10,000 virtual patients were derived by resampling subjects within the patients used in the development model.

As a pharmacokinetic/pharmacodynamic (PK/PD) index, we used the ratio of the day 28 free gatifloxacin AUC for a 24-h dosing interval and the MIC (fAUC/MIC), which has been shown to correlate to clinical outcome (35). The target PK/PD index was defined as fAUC/MIC of $\geqslant$125, which corresponds to a surrogate for maximal bactericidal effect and reduced probability of resistance (13, 14). The probability of target attainment (PTA) (36) was investigated with Monte Carlo simulations. The final model describing the pharmacokinetics in our study population was used together with the MIC distribution from an $in$ $vitro$ study investigating the activity of gatifloxacin against 234 clinical strains of $M$. $tuberculosis$ isolated in the southeast of Spain, published by Rodriguez et al. (3), with a MIC range of 0.06 to 16 mg/ml. The median MIC of the aforementioned study was 0.125 mg/ml, while the median MIC was 0.25 mg/ml with only 6 strains (2.5%) having MICs of $\geqslant$0.25 mg/ml.

The acceptable level for the PTA is still under debate, as is the most appropriate value for the target ratio of fAUC/MIC for optimal activity of gatifloxacin against $M$. $tuberculosis$. Therefore, the target ratio of fAUC/MIC as a function of the MIC with the 80% and 90% confidence intervals (CI) was derived. The lower boundary in an 80% CI of the total probability function is equivalent to 90% PTA (36). The PK/PD breakpoint was defined as the MIC at which the calculated PTA was 90%.

Ten thousand individual fAUCs were simulated based on the final model by integrating predicted drug concentrations from 0 to 24 h at steady state and thereafter correcting for serum protein binding, which was assumed to be 20% (1, 37). The PTA, i.e., the probability of fAUC/MIC being $\geqslant$125 across the range of MICs described by Rodriguez et al. (3), was derived. The cumulative fraction of response (CFR) (36) was calculated, representing the proportion of the population achieving fAUC/MIC of $\geqslant$125, given Monte Carlo simulation and the MIC distribution of $M$. $tuberculosis$ for 400, 600, and 800 mg once daily of gatifloxacin at steady state in combination with rifampin, isoniazid, and pyrazinamide. The CFR was calculated using equation 11:

$$\sum_{i=1}^{n} \text{PTA}_i \times F_i$$

(11)

where i indicates the MIC category ranked from lowest to highest MIC value, PTA is the PTA of each MIC category, and F is the fraction of the $M$. $tuberculosis$ population at each MIC category. F was calculated at each MIC as the number of isolates divided by the total number of isolates (234) yielding the frequency for each MIC.

**RESULTS**

The characteristics of the 169 patients contributing to this analysis are described in Table 1. More than one-half (59%) of the study participants were recruited at the South African study site, which had the highest frequency of HIV-infected patients (52% versus 12% in Benin and none in Guinea or Senegal).

The final gatifloxacin pharmacokinetic model described one-compartment with first-order elimination. Including an absorption transit model to account for the delay in absorption resulted in a drop in OFV of 125 points. The relationship between CL$_{CR}$ and CL/F was described using equations 3 and 4 based on the prior knowledge that gatifloxacin is largely eliminated by the kidneys (1), and this resulted in OFV reductions of 19 and 24 points, respectively, compared to models not accounting for CL$_{CR}$ or a combination of GFR-mediated and non-GFR clearance. In a 70-kg patient, gatifloxacin total CL/F was estimated to be 11.28 liters/h. Approximately 55% (6.17 liters/h) of CL/F was accounted for by renal filtration (a route scaled with CL$_{CR}$). Allometric scaling was applied to the remaining 45% (5.11 liters/h) of CL/F and to V/F (141 liters/h) using FFM as the optimal size descriptor, and the estimates were reported for a 70-kg patient (Table 2). F was 11.7% lower at steady state (day 28) than at the first dose. Age, sex, and HIV status had significant effects on the absorption rate constant, reducing interindividual variability of the parameter by 6.5, 3.4, and 17.7%, respectively (Table 2). The final model adequately described the concentration in plasma-time data at initial dose and at steady state as judged by the VPC (Fig. 1). Shrinkage for random effects between individuals and occasions ranged from 17 to 25% and from 38 to 99%, respectively. Shrinkage rates in IIV and IOV for CL/F were 25% and 42%, respectively. The epsilon (residual error) shrinkage was 39%.

Based on 10,000 Monte Carlo patient simulations, the median AUC$_{0-\infty}$ (41.2 $\mu$g·h/ml after the first dose) decreased to 35.4 $\mu$g·h/ml.
h/ml at steady state, following daily 400-mg doses of gatifloxacin in combination with rifampin, isoniazid, and pyrazinamide (Fig. 2). The median decrease in AUC$_{0-\infty}$ was 14.3% (5th and 95th percentiles, 90.4 and 61.5) to 35.4 g · h/ml (5th and 95th percentiles, 15.2 and 80.4) at steady state (day 28).

The PTA, i.e., the probability of patients achieving or exceeding the $f_{AUC}/MIC$ ratio of 125 at steady state, given the frequency distribution of MICs reported from 234 clinical isolates of M. tuberculosis, is shown in Fig. 3. The CFR, i.e., the proportion of the population achieving a $f_{AUC}/MIC$ of $\geq 125$ for daily 400-mg doses of gatifloxacin in combination with rifampin, isoniazid, and pyrazinamide, was calculated to be 61.4%. The respective CFRs for 600- and 800-mg doses of gatifloxacin were 79.3% and 88%.

The PK/PD breakpoint, defined as the MIC at which the calculated PTA was $\geq 90\%$, was 0.125 g/ml for daily gatifloxacin doses.

### TABLE 2 Parameter estimates based on the final gatifloxacin pharmacokinetic model$^a$

<table>
<thead>
<tr>
<th>Parameter (unit)</th>
<th>Estimate</th>
<th>% RSE</th>
</tr>
</thead>
<tbody>
<tr>
<td>(CL/F$_{GFR}$/STD (liters/h)</td>
<td>6.17</td>
<td>9.7</td>
</tr>
<tr>
<td>(CL/F$_{Other}$/STD (liters/h)</td>
<td>5.11</td>
<td>15.4</td>
</tr>
<tr>
<td>(V/F)$_{STD}$ (liters)</td>
<td>141</td>
<td>2.7</td>
</tr>
<tr>
<td>$F_{\text{first dose}}$</td>
<td>1 FIX</td>
<td></td>
</tr>
<tr>
<td>$F_{\text{steady-state}}$ (% change from $F_{\text{first dose}}$)</td>
<td>$-11.7$</td>
<td>17.4</td>
</tr>
<tr>
<td>$k_e$ ($h^{-1}$)</td>
<td>4.13</td>
<td>13.5</td>
</tr>
<tr>
<td>MTT (h)</td>
<td>0.65</td>
<td>8.1</td>
</tr>
<tr>
<td>$N$</td>
<td>12.6</td>
<td>19.7</td>
</tr>
</tbody>
</table>

**Covariate relationships**

- AGE-$k_e$ (%) | 3.2 | 15.2 |
- SEX-$k_e$ (%) | $-54.8$ | 10.7 |
- HIV-$k_e$ (%) | 61.9 | 38.4 |

**IIV**

- IIV$_{CL/F}$ (%) | 33.0 | 7.7 |
- IIV$_{V/F}$ (%) | 22.1 | 10.9 |

**IOV**

- IOV$_{CL/F}$ (%) | 33.0 | 5.7 |
- IOV$_{V/F}$ (%) | 13.2 | 13.9 |
- IOV$_{MTT}$ (%) | 44.9 | 12.3 |

**Residual variability**

- Additive error ($\mu g/ml$) | 0.341 | 5.1 |
- Proportional error (%) | 7.35 | 12.5 |
- Predose additive error ($\mu g/ml$) | 0.0418 | 40.7 |

$^a$IIV, interindividual variability expressed as coefficient of variation; IOV, interoccasion variability expressed as coefficient of variation; RSE, relative standard error reported on the approximate standard deviation scale; (CL/F$_{GFR}$/STD, the oral clearance in a typical patient with a median CLCR of 94 ml/min, representing drug cleared via glomerular filtration (GFR); (CL/F$_{Other}$/STD, the oral clearance not due to GFR in a typical 70-kg male patient and with a fat-free mass (FFM) of 55 kg. (V/F)$_{STD}$, typical apparent volume of distribution scaled to FFM and reported for a 70-kg male patient; $F$, bioavailability; MTT, mean transit time; $N$, number of transit compartments; AGE-$k_e$, % increase in $k_e$ for every year change from the median AGE of 29 years; SEX-$k_e$, % decrease in $k_e$ for female patients relative to male patients; HIV-$k_e$ (%), % increase in $k_e$ for patients with HIV relative to patients without HIV; predose additive error ($\mu g/ml$), additive error estimated uniquely for the predose concentrations following an unobserved dose; 1 FIX, fixed to 1 (not estimated).

**FIG 1** Visual predictive check (VPC) of the final gatifloxacin pharmacokinetic model stratified by occasion, i.e., first dose (a) and steady-state (day 28) (b). The solid line and the two dashed lines are the median and 5th and 95th percentiles, respectively, of the observed gatifloxacin concentrations in plasma. Shaded areas are the 90% prediction intervals for the median and 5th and 95th percentiles of simulated data. The open circles are observed concentrations.

**FIG 2** Box plot of gatifloxacin area under the concentration-time curve from 0 h to infinity (AUC$_{0-\infty}$) at first dose and at steady state (day 28) based on 10,000 virtual patients and Monte Carlo simulations of 400 mg gatifloxacin daily together with rifampin, isoniazid, and pyrazinamide. In this population, the median gatifloxacin AUC$_{0-\infty}$ of 41.2 g · h/ml (5th and 95th percentiles, 17.9 and 93.8) after the first dose was reduced on an individual level by 14.3% (5th and 95th percentiles, $-90.4$ and 61.5) to 35.4 g · h/ml (5th and 95th percentiles, 15.2 and 80.4) at steady state (day 28).

Population Pharmacokinetics of Gatifloxacin

September 2013 Volume 57 Number 9 aac.asm.org

4167
DISCUSSION

In our study, gatifloxacin exposure (bioavailability) was reduced following multiple doses when given together with rifampin, isoniazid, and pyrazinamide. This is in contrast to a single-dose study in healthy volunteers in which increased gatifloxacin exposure (AUC₀–∞) was observed (8). Hence, any initial increase in gatifloxacin concentrations attributable to concomitant use of rifampin, isoniazid, and pyrazinamide was counteracted by a reduction in gatifloxacin concentrations with repeated doses of the four drugs in combination. Exposure-related toxicity is thus unlikely to increase with repeated doses of gatifloxacin when it is given with rifampin, isoniazid, and pyrazinamide.

Two interesting observations emerge when comparing exposure after single-agent and combination treatment. First, the steady-state gatifloxacin AUC achieved in our study was slightly lower than the steady-state AUC reported in studies where patients were given the drug alone (6, 38). Second, gatifloxacin pharmacokinetic parameters (including bioavailability) were reported not to change following multiple doses when the drug was given on its own (1, 39). Gatifloxacin is a known substrate of the transmembrane efflux transporter protein P-glycoprotein (Pgp) (40), and rifampin induces the expression of Pgp (41). Hence, repeated doses of rifampin may result in reduced gatifloxacin systemic bioavailability due to increased efflux by Pgp expressed on enterocytes and hepatocytes. Gatifloxacin is principally (>80%) cleared unchanged via the kidneys (1). The overall reduction in gatifloxacin concentrations, following multiple doses in combination with
rifampin, isoniazid, and pyrazinamide, is thus likely to be the net result of drug-drug interactions observed both following single doses and at steady state.

Reduced gatifloxacin clearance and recovery in urine were reported following concomitant dosing with probenecid, suggesting that tubular secretion may contribute to its elimination (1). In our study, gatifloxacin clearance increased with creatinine clearance (ClCr) and patient weight (FFM). Scaling drug clearance to both FFM and ClCr allowed us to estimate that approximately 53% of the dose was cleared via glomerular filtration. Using ClCr as our proxy for renal filtration might, however, overestimate the contribution of this pathway to drug clearance, since creatinine is actively secreted by the peritubular capillaries of the kidney (42). The remaining 47% of gatifloxacin’s clearance was scaled to FFM and accounted for drug cleared via all pathways other than glomerular filtration.

Gatifloxacin bioavailability was predicted to be approximately 12% lower at steady state than after an initial dose. This, combined with increased patient weight (FFM) and ClCr (ml·min⁻¹) at the second occasion, resulted in a 14.3% reduction of AUC₀→∞ at steady state. The reduction in gatifloxacin exposure following multiple doses is unlikely to be clinically significant, as on an individual level gatifloxacin AUC₀→∞ could increase by as much as 90% or decrease by as much as 62% between the two occasions due to high IOV in CL/F. Age, sex, and HIV infection status were also identified as having significant covariate effects on the absorption rate constant. However, these covariates are also unlikely to be clinically relevant, as changes of the absorption rate do not alter the average steady-state concentration.

Based on 10,000 Monte Carlo simulations using the final model, 62, 79, and 88% of our study population were predicted to achieve the target fAUC/MIC ratio of ≥125 following daily 400-, 600-, and 800-mg respective doses of gatifloxacin. Only when the MIC of gatifloxacin fell below 0.125 μg/ml could 90% of the study population, irrespective of dose, achieve the target ratio. The simulations showed that at 800-mg daily doses of gatifloxacin, approximately 90% of the population would achieve the target ratio when the MIC was ≤0.25 μg/ml. These results suggest that the current 400-mg daily dosing of gatifloxacin does not achieve optimal drug exposure with respect to the MIC distribution used. However, using the target plasma fAUC/MIC ratio of ≥125 to predict the optimal dose of gatifloxacin in this context is a simplification and has its limitations. Forrest et al. (13) demonstrated that bacteriological and clinical outcomes correlated best with the pharmacodynamic index of an AUC/MIC of ≥125 in 74 acutely ill patients treated with ciprofloxacin for lower respiratory tract infections. In that study, an AUC/MIC ratio of ≥125 was significantly correlated with a faster bacterial eradication rate, which may decrease the likelihood of antibacterial resistance. Setting the target to a lower value (i.e., targets of AUC/MIC ratio of <125) could potentially create needless selective pressure, increasing the chance of resistance especially with a long duration of therapy (e.g., 4 months). Notably, in a review by Schentag et al. (14), the pharmacodynamic index target AUC/MIC ratio of ≥125 is recommended for both Gram-positive and Gram-negative organisms. Although fAUC/MIC is widely accepted as a correlate of fluoroquinolone efficacy (43), more work is required to determine whether an AUC/MIC of ≥125 truly correlates with in vivo efficacy against M. tuberculosis. In this work, we also present the total probability function for different gatifloxacin doses, which is not dependent on the target (Fig. 4). The lower boundary in the 80th percentile of the total probability function is equivalent to 90% PTA. The 90% PTA for any new future target can be visualized from this plot. Interestingly, a plasma AUC/MIC ratio of 112 to 220 was associated with optimal survival among patients with tuberculosis meningitis who were treated with a regimen containing gatifloxacin, levofloxacin, or ciprofloxacin in addition to standard antituberculosis treatment (44). Although this ratio is in keeping with the target AUC/MIC of ≥125, the optimal values for the plasma AUC/MIC ratios for pulmonary tuberculosis and tuberculosis meningitis are likely to differ due to differences in tissue penetration and immunity at the site of action. Drug action occurs within pulmonary compartments, including epithelial cells and macrophages, where drug concentrations exceed those found in plasma (45). Assuming higher fAUC in pulmonary compartments, more patients could achieve the target fAUC/MIC ratio of ≥125. On the other hand, there are concerns that administering higher doses of gatifloxacin would increase the risk of toxicity such as dysglycemia. Lastly, the optimal dose of gatifloxacin would need to take into account the efficacy and safety profiles of the drug in the context of the contributions from companion drugs in the multidrug regimen and patient immunity.

Further limitations of our study include failure to measure free gatifloxacin concentrations and lack of study-specific information about the MICs. We assumed a 20% plasma protein binding for gatifloxacin that is independent of concentration (1), and we used the MIC distribution obtained from 234 clinical isolates of M. tuberculosis from Spain (3). The M. tuberculosis population reported in the Spanish study was slightly more sensitive to gatifloxacin than to moxifloxacin and levofloxacin, with reported MIC₅₀ of 0.25 and 0.5 μg/ml, respectively. In agreement with the Spanish study, a similar gatifloxacin MIC₉₀ of 0.25 μg/ml was reported against clinical isolates of M. tuberculosis obtained from numerous sources with broad geographical distribution (46). Additionally, the aforementioned study reported an MIC₉₀ and distribution range of MIC for M. tuberculosis similar to that reported in the Spanish study. Thus, our assumption that the frequency distribution of gatifloxacin MIC reported in the Spanish study correlates to the MIC distribution found within our study population appears to be valid. Nonetheless, as demonstrated by Peloquin et al. (38), a change in the MIC distribution (i.e., published versus actual MICs determined from clinical isolates obtained from study patients) can radically change the fAUC/MIC ratio. Since our study did not measure the MICs of M. tuberculosis in the study population, it is feasible that the true effective MIC could be lower. Moreover, the MICs reflect the activity of gatifloxacin alone; we did not account for synergism or antagonism within the regimen. The relevance of these findings needs to be evaluated alongside the eventual clinical outcomes of the study overall.

Conclusion. Although increased gatifloxacin exposure was observed in a previous single-dose study, gatifloxacin exposure, expressed as AUC₀→∞, declined following multiple doses of the 4 drugs in the multidrug regimen. Hence, exposure-related toxicity is unlikely to increase with repeated doses of gatifloxacin when given concomitantly with rifampin, isoniazid, and pyrazinamide. Based on predictions of fAUC/MIC and the derived proportion of the population achieving optimal bactericidal effect and reduced
probability of resistance (CFR), the CFR of the clinically used dose of 400 mg daily was 61%; simulations showed that doubling the dose would result in increasing the CFR to 88%. However, the pharmacokinetics of gatifloxacin needs to be studied in relation to efficacy and safety in pulmonary tuberculosis patients on the multidrug regimen in order to evaluate the optimal gatifloxacin exposure in this context.

ACKNOWLEDGMENTS

The study was supported by grant ICA4-CT 2002-10057 from the World Health Organization (WHO)/Special Programme for Research and Training in Tropical Diseases (TDR) and the Research Institute for Development (IRD).

We acknowledge the contributions of the clinical sites and patients, without which this study would not have been possible. P.L.O. and C.L. are staff members of the WHO. We are responsible for the views expressed in this publication, and they do not necessarily represent the decisions, policy, or views of the WHO.

REFERENCES

37. Gajjar DA, Lacrota FP, Uderman HD, Kollia GD, Duncan G, Birkhofer


